{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:01:56Z","timestamp":1790913716655,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Hematol Blood Transfus"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s12288-024-01797-9","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T14:02:21Z","timestamp":1720447341000},"page":"558-563","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Imatinib Mesylate Causes Potential Cardiac Dysfunction in Patients With Chronic Myeloid Leukemia: the Results of a Case\u2013control Study"],"prefix":"10.1007","volume":"40","author":[{"given":"Gowri","family":"Shankar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankur","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankur","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Jandial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelam","family":"Varma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arihant","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alka","family":"Khadwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9495-9789","authenticated-orcid":false,"given":"Pankaj","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,8]]},"reference":[{"key":"1797_CR1","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/jnci\/djr060","volume":"103","author":"C Gambacorti-Passerini","year":"2011","unstructured":"Gambacorti-Passerini C, Antolini L, Mahon FX et al (2011) Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 103:553\u2013561","journal-title":"J Natl Cancer Inst"},{"key":"1797_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12288-019-01074-0","volume":"35","author":"U Yanamandra","year":"2019","unstructured":"Yanamandra U, Malhotra P (2019) CML in India: Are We There Yet? Indian J Hematol Blood Transfus 35:1\u20132","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"35","key":"1797_CR3","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","volume":"33","author":"JJ Moslehi","year":"2015","unstructured":"Moslehi JJ, Deininger M (2015) Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol 33(35):4210\u20134218","journal-title":"J Clin Oncol"},{"key":"1797_CR4","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","volume":"123","author":"E Jabbour","year":"2014","unstructured":"Jabbour E, Kantarjian HM, Saglio G et al (2014) Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 123:494\u2013500","journal-title":"Blood"},{"key":"1797_CR5","doi-asserted-by":"crossref","unstructured":"Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S et al (2016) Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 30(5):1044\u20131054","DOI":"10.1038\/leu.2016.5"},{"key":"1797_CR6","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/nm1446","volume":"12","author":"R Kerkel\u00e4","year":"2006","unstructured":"Kerkel\u00e4 R, Grazette L, Yacobi R et al (2006) Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12:908\u2013916","journal-title":"Nat Med"},{"key":"1797_CR7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.leukres.2010.08.020","volume":"35","author":"ZR Estabragh","year":"2011","unstructured":"Estabragh ZR, Knight K, Watmough SJ et al (2011) A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib. Leuk Res 35:49\u201351","journal-title":"Leuk Res"},{"key":"1797_CR8","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1182\/blood-2007-01-070144","volume":"110","author":"E Atallah","year":"2007","unstructured":"Atallah E, Durand JB, Kantarjian H et al (2007) Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 110:1233\u20131237","journal-title":"Blood"},{"issue":"4","key":"1797_CR9","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/bjh.14608","volume":"177","author":"M Minami","year":"2017","unstructured":"Minami M, Arita T, Iwasaki H, Muta T, Aoki T, Aoki K et al (2017) Comparative analysis of pulmonary hypertension in patients treated with imatinib, nilotinib and dasatinib. Br J Haematol 177(4):578\u2013587","journal-title":"Br J Haematol"},{"key":"1797_CR10","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1172\/JCI24838","volume":"115","author":"RT Schermuly","year":"2005","unstructured":"Schermuly RT, Dony E, Ghofrani HA et al (2005) Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 115:2811\u20132821","journal-title":"J Clin Invest"},{"key":"1797_CR11","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1093\/eurheartj\/ehu035","volume":"36","author":"AM Shah","year":"2015","unstructured":"Shah AM, Campbell P, Rocha GQ, Peacock A, Barst RJ, Quinn D et al (2015) IMPRES Investigators. Effect of imatinib as add-on therapy on echocardiographic measures of right ventricular function in patients with significant pulmonary arterial hypertension. Eur Heart J 36:623\u201332","journal-title":"Eur Heart J"},{"key":"1797_CR12","first-page":"45","volume":"12","author":"S Parasuraman","year":"2016","unstructured":"Parasuraman S, Walker S, Loudon BL, Gollop ND, Wilson AM, Lowery C et al (2016) Assessment of pulmonary artery pressure by echocardiography\u2014A comprehensive review. Int J Cardiol Heart Vasc 12:45\u201351","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"4","key":"1797_CR13","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","volume":"29","author":"SF Nagueh","year":"2016","unstructured":"Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T et al (2016) Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American society of echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr 29(4):277\u2013314","journal-title":"J Am Soc Echocardiogr"},{"issue":"1","key":"1797_CR14","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1200\/JGO.2015.002667","volume":"3","author":"P Ganesan","year":"2016","unstructured":"Ganesan P, Kumar L (2016) Chronic myeloid leukemia in India. J Glob Oncol 3(1):64\u201371","journal-title":"J Glob Oncol"},{"key":"1797_CR15","doi-asserted-by":"publisher","first-page":"186","DOI":"10.4103\/0971-5851.123728","volume":"34","author":"P Malhotra","year":"2013","unstructured":"Malhotra P, Varma N, Varma S (2013) A short report on chronic myeloid leukemia from Post Graduate Institute of Medical Education and Research, Chandigarh. Indian J Med Paediatr Oncol 34:186\u2013188","journal-title":"Indian J Med Paediatr Oncol"},{"key":"1797_CR16","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S0140-6736(07)61510-4","volume":"370","author":"P Malhotra","year":"2007","unstructured":"Malhotra P, Varma S (2007) Chronic myeloid leukaemia in India. Lancet 370:1127","journal-title":"Lancet"},{"issue":"2","key":"1797_CR17","first-page":"99","volume":"24","author":"N Paul","year":"2018","unstructured":"Paul N (2018) Reynolds, Pulmonary arterial hypertension In Asia, as elsewhere, still a lethal disease despite modern treatment. Respirology 24(2):99\u2013100","journal-title":"Respirology"},{"key":"1797_CR18","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG et al (2006) Five year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408\u20132417","journal-title":"N Engl J Med"},{"key":"1797_CR19","doi-asserted-by":"publisher","unstructured":"Moslehi JJ, Aras MA, Oehler VG, Thompson JE, McCloskey JK, Heinrich MC, et al. (2023) Longitudinal, prospective cardiovascular and metabolic risk in treatment-naive patients with chronic myeloid leukemia in chronic phase (CML-CP) starting tyrosine kinase inhibitor (TKI) therapy in a real-world setting. J Clin Oncol 41(suppl). https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.7053","DOI":"10.1200\/JCO.2023.41.16_suppl.7053"},{"issue":"Suppl 1","key":"1797_CR20","first-page":"2893","volume":"130","author":"C Gurguis","year":"2017","unstructured":"Gurguis C, de Armas LR, Kantarjian HM, Boddu PC, Jain P, Borthakur G et al (2017) Echocardiographic findings in patients (pts) receiving tyrosine kinase inhibitors (TKIs) for the treatment of chronic myeloid leukemia (CML). Blood 130(Suppl 1):2893","journal-title":"Blood"},{"issue":"3","key":"1797_CR21","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1253\/circj.CJ-15-0064","volume":"79","author":"EM Jeong","year":"2015","unstructured":"Jeong EM, Dudley SC Jr (2015) Diastolic dysfunction. Circ J 79(3):470\u2013477","journal-title":"Circ J"},{"issue":"3","key":"1797_CR22","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jphs.2022.07.008","volume":"150","author":"K Chiba","year":"2022","unstructured":"Chiba K, Kambayashi R, Onozato M, Goto A, Izumi-Nakaseko H, Takei Y et al (2022) Imatinib induces diastolic dysfunction and ventricular early-repolarization delay in the halothane-anesthetized dogs: Class effects of tyrosine kinase inhibitors. J Pharmacol Sci 150(3):154\u2013162","journal-title":"J Pharmacol Sci"}],"container-title":["Indian Journal of Hematology and Blood Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-024-01797-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12288-024-01797-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-024-01797-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T22:06:21Z","timestamp":1729980381000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12288-024-01797-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,8]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1797"],"URL":"https:\/\/doi.org\/10.1007\/s12288-024-01797-9","relation":{},"ISSN":["0971-4502","0974-0449"],"issn-type":[{"value":"0971-4502","type":"print"},{"value":"0974-0449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,8]]},"assertion":[{"value":"16 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"IRB approval for this study was obtained from the ethics committee of Postgraduate Institute of Medical Education and Research, Chandigarh, India.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Clearance"}},{"value":"The authors state that a written and informed consent was obtained from the patients prior to publication of any material pertaining to their case. In case of patients\u2009<\u200918\u00a0years, consent from their guardians was obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"No AI-based tool was used in drafting this paper.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Artificial Intelligence"}}]}}